About Us

AblaCor Medical Corporation was founded in 2013 and is based in Massachusetts.  The company was formed to address atrial fibrillation (AF), a significant cardiac rhythm disorder and a leading cause of stroke.  Since its formation, AblaCor has assembled an excellent team, received broad endorsement from prominent, key-opinion leading physicians, and is developing a game-changing product that will fundamentally improve the treatment of AF.

AblaCor’s goal is to develop an ablation catheter technology that will effectively and reliably treat patients with AF in their first procedure.  Effective treatment will eliminate the burdens of AF for many hundreds of thousands of individuals and help to prevent the resulting higher incidence of stroke.

AblaCor was a finalist in the 2012 MassChallenge competition, a finalist in the 2012 Massachusetts Medical Device Development Center  (M2D2) New Venture Competition, and was honored as part of Massachusetts Biotechnology Council’s (MassBIO) 2013 MassConnect program.  AblaCor’s technology is covered with two issued patents and 8 patents pending.


AblaCor regularly participates in medical conferences such as the Heart Rhythm Society. 
To see a bit about our participation in the 2014 meeting, click
here.

Team

Martin SklarAblaCor is led by Martin Sklar, founder & CEO, a highly accomplished Leader, Inventor, Consultant and Engineer. He has extensive experience in business development, intellectual property development, project management, design engineering, manufacturing engineering, technical analysis, and product introduction in the medical technology industry. He founded Automated Medical Instruments, Inc. in 1992, now AblaCor Medical Corporation as of January 2013, to focus on developing remote controlled instruments for minimally invasive medical applications, including the present project to treat Atrial Fibrillation. 

Mr. Sklar’s accomplishments have contributed to over $1 Billion in revenues for clients and employers from start-up through Fortune 100 companies.  He has 10 issued patents and 10 patents pending.  In 2001, Martin co-founded, the non-profit organization, Medical Development Group (MDG), a major New England based medical technology industry association.  He was its first president and a board member until 2012.  In 2002, he co-founded AlvaMed, LLC.  In 2006, he co-founded Medical Development Partners, LLC., both medical technology consulting companies.

Mr. Sklar exhibits profound interest in medical automation and robotics. He has given his presentation, ‘Improving Healthcare Outcomes and Reducing Costs Through Medical Automation’ to numerous audiences. He is a member of several professional associations including MDG, Heart Rhythm Society, and the Biomedical Engineering Society. His education includes a Master of Engineering degree from Dartmouth College’s Thayer School of Engineering and a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.

Jim Bricker, MBA, has served as President & CEO of six high tech companies, two of which he founded, and as a business consultant, aiding start-ups in the business planning and fundraising stages.  Early in his career, he worked for three Fortune 500 companies.  The products and services with which he has been involved range from electromechanical and electronic products (including aircraft security systems and interactive “talking” world globes) to hospital products (including catheters) to software products (including hospital emergency room triage software).  He has successfully engaged individual investors, Angel groups and Venture Capital groups in his companies, and received investments from large companies as well as managed the sale of small companies to large companies in the course of his business career.  Mr. Bricker was involved with the MIT Enterprise Forum almost from its inception, and has been an active member of the Harvard Business School Alumni Association.  Most recently, Mr. Bricker has served as a Financial Advisor for the Bulfinch Group in Needham, Massachusetts.  He holds two Bachelor’s degrees from M.I.T.: a B.S. in Mechanical Engineering and a B.S. in Management (from the Sloan School); as well as an MBA from the Harvard Business School.

Joyce CollegeJoyce College, MBA, RN, has demonstrated leadership in strategic planning, clinical marketing, program and product management, and commercialization.  She has a passion for innovation in medical technology and the value it brings to patients, clinicians and the healthcare system.  She is Director of Strategic Management for AblaCor.  Ms. College has been a consultant and medical writer for Covidien.  She has worked as a clinical marketing consultant for medical device companies and was a principal of Medical Development Partners, LLC, a medical product development and commercialization company.  For over 16 years, she was a product and program manager for Fresenius Medical Care North America, the world leader in the manufacture and delivery of dialysis products and services.  While at Fresenius, Ms. College had the opportunity to launch several significant treatments for renal patients including the drug, Epogen® and diagnostic services for the Dialysis Services Division.

She has served as Vice President, Secretary and Board Member of the Medical Development Group (MDG), a major industry association and led several task forces and strategic efforts for the organization. Ms. College is also a member of Women in Healthcare Management, the American Nephrology Nurses Association and the Life Science Committee of the New England Israel Business Council.  She holds a BS with a Major in Nursing and an MBA in Healthcare Management, both from Boston University.


Michael Drues, PhD, is the President of Vascular Sciences, an education, training, and consulting company offering a broad range of services to medical device, pharmaceutical and biotechnology companies including stimulating and innovative educational programing, brain-storming sessions, prototype design, product development, benchtop and animal testing, regulatory strategy & clinical trial design, FDA presentation preparation & defense, reimbursement, clinical acceptance, business development and  technology assessment.

Dr. Drues received his B.S., M.S., and  Ph.D. degrees in Biomedical Engineering from Iowa State University and has worked for and consulted with leading medical device, pharmaceutical and biotechnology companies ranging in size from start-ups to Fortune 100 companies. He also consults to the U.S. Food and Drug Administration (FDA), Health Canada, the US and European Patent Offices, the Centers for Medicare and Medicaid Services (CMS) and other regulatory and governmental agencies around the world. As an internationally recognized expert and featured keynote speaker, Dr. Drues presents frequently on cutting-edge medical technologies & regulatory affairs.  He also conducts seminars and short courses for medical device, pharmaceutical & biotechnology companies, FDA, Health Canada, US and European Patent Offices, CMS and other regulatory and governmental agencies around the world.


Robert
 Flaherty has served as President and Chief Executive Officer of Athena Diagnostics, Inc., a subsidiary of Thermo Fisher Scientific, Inc.. With $100M+ in revenue and $55M in EBITDA, Athena Diagnostics, was one of the nation’s largest, most profitable and fastest growing specialty commercial reference laboratories. Athena identified, developed, launched and marketed directly to physicians 320 innovative and proprietary diagnostic testing services. Mr. Flaherty was President of Becton Dickinson Medical, the largest and most profitable operating unit of Becton Dickinson & Company, along with Becton Dickinson’s worldwide operating unit, Vacutainer Systems. Mr. Flaherty has served on the Boards of Directors and has been chairman of the compensation committees and a member of the audit committees of Datatrak International, AngioDynamics, Inc., Xtent, Inc., Repromedix, Inc. all on NASDAQ as well as Synthes, Inc., then privately held, but now part of Johnson & Johnson Family of Companies, and Atherotech, Inc.  He has a B.S. in Industrial Engineering from Lehigh University and an MBA from Harvard Business School.


Howard Ring is a Mechanical Engineer with a Bachelor’s and Master’s degree, a Professional Engineering license, and 7 US patents.  With strengths in product design, product and manufacturing support, system engineering, and project management of high-tech, high-precision machines (laser, inkjet and other imaging/printing equipment).  He has proven success in taking products from development through prototype, design and manufacturing.  He is skilled in design, product integration, concurrent engineering, low-cost manufacturing, cost reduction, design for reliability and serviceability, and new product introduction.  Mr. Ring is experienced in electro-mechanical-optical design of copier and laser printers, including thermal, magnetics, drives and mechanisms, electronic packaging, air flow cooling, airborne particle filtration, liquid particle filtration, plastic properties, thermal management, acoustic noise measurement and control, vacuum, pneumatics, heat transfer and fluid flow.

Jonathan Schiff brings a wealth of experience in Class II & Class III electromechanical medical device development, including the overall design control process, usability engineering, standards compliance engineering, systems integration, verification and validation testing, risk management, external resource management, technical writing, and support of FDA (510k and PMA) and EU device submissions. Jonathan also brings valuable experience and perspective on building design control procedures, the technical aspects of the device commercialization process, and post-launch compliance requirements.  
 
Jonathan holds a Bachelor of Science degree in Bioengineering from Columbia University in New York City and a Master of Science degree in Electrical Engineering from Northeastern University in Boston.  He is currently at Microchips Biotech in Lexington, MA working to commercialize active implantable drug delivery systems. Prior to that, he spent 6 years in R&D at Heartware, Inc. in Framingham, MA where he played a key role in the development and commercialization of Ventricular Assist Device systems. Jonathan has also worked in R&D at GE Healthcare in developing image guided surgical instrumentation, at Seacoast Technologies in developing disposable brain cooling devices, and at C.R. BARD’s Electrophysiology division (now part of Boston Scientific) in working on cardiac mapping and ablation systems.


Roy Wallen brings over 25 years of experience in product marketing, new product development, and operations, having overseen the successful launch of new technologies in medicine.  Specific application areas include cardiology (arrhythmia management, interventional procedures, electrophysiology), critical care medicine, anesthesiology (monitoring and anesthesia delivery), cardiac surgery (monitoring and circulatory support), in vitro and in vivo diagnostics, mobile health, and sterilization systems.

Mr. Wallen’s global experience includes worldwide product marketing, developing and directing a sales organization in Europe, and regulatory and reimbursement support in Japan.  A significant portion of his product marketing and market development work (8 years) was done in Germany, where he became fluent in the local language and the business culture of Europe.  Market development in the Asia-Pacific rim included development and support of distributors in Korea, southeast Asia, Australia, and New Zealand.  Work in Japan included developing distributors and a lengthy program through a direct subsidiary for importation, regulatory approval, and reimbursement of a new medical product.

Building on this strong base, Mr. Wallen established
Directional Healthcare Advisors, LLC, a Massachusetts company that provides advisory services in the areas of product development and marketing strategy, market segmentation, business line P&L assessment, business development, and go-to-market implementation.


Scientific Advisory Board

Jeremy N. Ruskin, MD, is Director of the Cardiac Arrhythmia Service at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Dr. Ruskin received his undergraduate degree from Tufts University and his medical degree from Harvard Medical School. He completed his residency in Internal Medicine at Beth Israel Hospital in Boston and his fellowship in Cardiovascular Disease at the Massachusetts General Hospital. He received his training in clinical cardiac electrophysiology at the USPHS Hospital in Staten Island, New York under the mentorship of Dr. Anthony Damato. 

In 1978, Dr. Ruskin founded the first cardiac arrhythmia service and clinical electrophysiology laboratory in New England and one of the first such services in the United States. As founder and director of the Massachusetts General Hospital Fellowship Training Program in Clinical Cardiac Electrophysiology, he has been responsible for the training and mentorship of more than 110 clinical and research fellows in the subspecialty of cardiac arrhythmias over the past 36 years, many of whom are in leadership positions at academic centers throughout the world. His major research interests include the mechanisms and management of atrial fibrillation, new antiarrhythmic drugs and innovative technologies for catheter ablation of atrial fibrillation, the mechanisms and prevention of ventricular arrhythmias and sudden cardiac death, risk stratification for sudden death, the role of arrhythmia control devices in the prevention of sudden cardiac death, the proarrhythmic effects of cardiac and non-cardiac drugs and cardiac safety issues in new drug and device development. He is an author of more than 400 original scientific publications, chapters, reviews, and monographs. Dr. Ruskin is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology and the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award.


http://www.bmc.org/findaphysician/renderimage/displayimage.aspx?id=1037Kevin Monahan, MD, is Associate Professor of Medicine at the Boston University School of Medicine and the Boston Medical Center.  He has extensive expertise in the areas of electrophysiology and rhythm management, with over 50 peer-reviewed publications.  Dr. Monahan received his medical degree from the University of Connecticut Medical School and completed residency and fellowship programs at the Beth Israel Hospital in Boston.








Lawrence Rosenthal, PhD, MD, is Director, Cardiac Devices and Electrophysiology at the University of Massachusetts Memorial Medical Center.  He is also affiliated with Webster Medical Center.  His clinical interests include drug and ablation therapies for supraventricular and ventricular arrhythmias, including atrial fibrillation and ischemic VT, cardiac devices including ICD's and pacemakers, lead explantation, device therapy for heart failure including cardiac resynchronization.  Dr. Rosenthal received his medical degree from Albert Einstein College of Medicine of Yeshiva University, his training in medicine from UMass Medical Center, and his training in cardiology at the John Hopkins Hospital. He and has been in practice for 16 years.





Business Advisors

Edward E. Berger, Ph.D., has nearly 30 years’ experience in health services, medical technology, and life sciences corporate communications, strategic planning, reimbursement, and regulatory policy.  As a member of the senior management teams of Fresenius Medical Care, Thermo Cardiosystems and ABIOMED, Dr. Berger exercised responsibility for strategically sensitive communications with government agencies, news media, and investors and served as principal corporate spokesperson through numerous crises and other high visibility events.  Through his consultancy, Larchmont Strategic Advisors, he helps life sciences companies create and implement integrated strategies to address the obstacles and opportunities they face in their efforts to secure public and private insurer coverage and optimal reimbursement for new or evolving technologies.  Focusing on issues that arise at the intersection of public policy, corporate strategy development, and internal and external advocacy, Dr. Berger helps clients to deal effectively with the strategic challenges posed by the rapidly evolving healthcare regulatory and policy environment.  His clients have included companies in fields such as mechanical circulatory support, cardiology, orthopedics, neural monitoring and neuromodulation, gastrointestinal surgery, pulmonary medicine, nuclear medicine, diagnostic imaging, clinical laboratory testing, and personalized medicine.

Dr. Berger also serves as President of cardiothoracic device developer Coraux Technologies, LLC and as a Director of Atanse, Inc., an early stage neurosurgical instrument company.  He is a member of Mass Medical Angels, a mentor in Boston University’s IGNITE program, and Past President of the Medical Development Group, a 400 member professional association of individuals professionally committed to the medical device and related life sciences business sectors.  He has a Bachelor’s Degree in Government from Harvard College, and earned his Ph.D. in Political Science at Boston University, where he was later Assistant Professor of Political Science and Chair of the Urban Affairs and Planning program.

Robert DeNobleRobert A. DeNoble, MBA, CPA, founded RDA Healthcare Consulting in 1998 to provide business and financial consulting services to emerging health care companies focused on biotechnology, medical devices, and systems designed to improve the delivery of quality medical care.  Specific experience and focus includes preparing business plans, multi-year financial projections, and funding requirements for the business. Recent projects included assisting an early stage biotech company prepare and present business and financial plans used in successfully raising over $15M from VCs, assisting a health care provider develop and implement an operational turnaround plan, and serving on the founding team for a biosciences company. Prior to RDA Healthcare Consulting, Mr. DeNoble spent 18 years in the health care practice at KPMG and served in a senior executive capacity at several health care institutions.  He is also the founder and leader of the Harvard Business School Healthcare Alumni Association.


Arthur HillerArthur Hiller is the Chief Business Officer at Geppetto Avatars, experts in the fields of Natural Language Processing, artificial intelligence, robotics, and multimedia developing novel approaches to patient education and disease management.  His role is to implement change in the paradigm of clinical care through the development of relationships with customers, partners and collaborators, and through identification of synergistic technologies that support and enhance the product platform.  Mr. Hiller has extensive experience in biotechnology, pharmaceutical and life sciences with broad functional experience that includes expertise in building and expanding commercial operations, new product development and marketing; sales and sales management; business and corporate development, including licensing, merger, and acquisition; managed care, health care information technology, manufacturing, and distribution.


Barry HorwitzBarry Horwitz is president of Horwitz & Company LLC, a management consulting practice focused on helping senior management with growth initiatives and strategic planning.  His clients include both for-profit and nonprofit organizations.  Mr. Horwitz’s prior consulting experience includes several years with The Boston Consulting Group where he focused on corporate strategy development for Fortune 500 clients.  His experience with early-stage companies includes his role as co-founder and COO of a venture-backed Internet company and as VP of Marketing and Strategy for an enterprise software company.  Mr. Horwitz has also had management experience with larger organizations, having held senior level positions in marketing and strategic planning at two multi-billion-dollar retail chains. He received his MBA from Harvard Business School and his BA degree in Economics from Colby College, and is an Executive in Residence at the school of management at Boston University, where he teaches courses in strategy and entrepreneurship.

Kim Vandeweyer has been active in the medical device industry since 1999.  His experience is as a sales manager, country manager and clinical specialist with Biosense Webster, Cryocath Technologies, NMT Medical Inc., Lifetech Scientific Inc., Broncus Technologies Inc., Sigma Medical and now as a consultant for Total Medical Solutions BV and owner of ConDis Medical.  With a scientific bachelor education followed by years of clinical experience, he has trained physicians, nurses, in-house staff and distribution partners.  Each of these challenges has directly helped him to successfully investigate clinical needs and implement new technologies in the area of electrophysiology, interventional cardiology, interventional radiology, and structural heart.  In his commercial roles, he has been responsible for sales generation, establishing business plans, and overseeing P&L plans. On a daily basis, he gathers knowledge in project management, good clinical practice, and sales methods. He received an MBA in 2010 in General Management and Entrepreneurship.


Website Builder